Published in Lab Law Weekly, January 19th, 2007
This multi-site project involves collecting thousands of tumor tissues and clinical data from patients from across the state of Florida. Moffitt will utilize sophisticated technology with Merck to analyze each patient's tumor to identify its genetic "fingerprints" or markers specific to that tumor. By studying and comparing patient's response to specific treatments, scientists will be able to identify drugs that will give physicians the knowledge they need to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly